Peroxisomes and peroxisomal disorders: The main facts
Marco Fidaleo

To cite this version:
Marco Fidaleo. Peroxisomes and peroxisomal disorders: The main facts. Experimental and Toxicologic Pathology, Elsevier, 2010, 62 (6), pp.615. <10.1016/j.etp.2009.08.008>. <hal-00644263>

HAL Id: hal-00644263
https://hal.archives-ouvertes.fr/hal-00644263
Submitted on 24 Nov 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Peroxisomes and peroxisomal disorders: The main facts

Marco Fidaleo

PII: S0940-2993(09)00235-8
DOI: doi:10.1016/j.etp.2009.08.008
Reference: ETP 50398

To appear in: Experimental and Toxicologic Pathology

Received date: 31 January 2009
Accepted date: 16 August 2009

Cite this article as: Marco Fidaleo, Peroxisomes and peroxisomal disorders: The main facts, Experimental and Toxicologic Pathology, doi:10.1016/j.etp.2009.08.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Title: Peroxisomes and Peroxisomal disorders: the main facts.

Author: Marco Fidaleo

Address: Department of Cellular and Developmental Biology, University of Rome “La Sapienza”, P.le Aldo Moro 5, 00185 - Rome, Italy

Corresponding Author:
Marco Fidaleo
Department of Cellular and Developmental Biology, University of Rome “La Sapienza”, P.le Aldo Moro 5, 00185 - Rome, Italy
Telephone number: 0039(0)649912317
FAX number: 0039(0)649912351
e-mail: marco.fidaleo@uniroma1.it
Abstract

The importance of peroxisomes for human health is highlighted by the number of peroxisomal disorders (PDs), diseases associated to peroxisome biogenesis disorders and peroxisomal enzyme/transporter deficiencies. Currently, many physiological/biosynthetic mechanisms involved in these illnesses have been elucidated, but PDs remain incurable. This review examines the most important aspects concerning peroxisomes (i.e. Peroxisome proliferation, Peroxisome biogenesis, Metabolic functions of mammalian peroxisomes) and presents the most significant trends and advances in the study of peroxisomal disorders.

Key words: Peroxisomes; Peroxisomal biogenesis; Peroxisomal metabolism; Peroxisomal disorders; Peroxisomal β-oxidation.

Outline

1. Introduction
2. Peroxisome proliferation
3. Peroxisomal biogenesis
   3.1 Formation of peroxisome membrane (importance of ER)
   3.2 Synthesis and import of proteins in peroxisomal matrix
   3.3 Synthesis and transport of proteins of peroxisomal membrane
4. Metabolic functions of mammalian peroxisomes
   4.1 Peroxisomal β-oxidation
      4.1.1 Peroxisomal β-oxidation specific substrates
      4.1.2 Activation and transport of fatty acids
   4.2 Fatty acid α-oxidation
4.3 Cholesterol biosynthesis

4.4 Metabolism of bile acids

4.5 Role of peroxisomes in biosynthesis of fatty acids

4.6 Synthesis of plasmalogens

4.7 Oxidative stress

5. Peroxisomal disorders

5.1 Peroxisome biogenesis disorders (PBDs)

5.2 Peroxisomal enzyme/transporter deficiencies (PEDs)

6. Conclusion

**Abbreviations**

**ABC**: ATP-binding cassette

**ABCD gene**: ATP-binding cassette, subfamily D

**ACO**: acyl-CoA oxidase

**ACS**: Acyl-CoA synthetase

**ALD**: Adrenoleukodystrophy

**BCFA**: Branched-chain fatty acid

**CHO**: Chinese hamster ovary

**CuZnSOD**: Copper-zinc superoxide-dismutase

**DEHP**: Di-(2-ethylhexyl) phthalate

**DHA**: Docosahexaenoic acid

**DHCA**: 3α,7α-dihydroxy-5β-cholestanoic acid

**DLP-1**: Dynamin-Like Protein 1

**DRP**: Dynamin-related proteins
ER: Endoplasmic reticulum

FA: Fatty acid

FAT/CD36: fatty acids translocase, CD36

FPP: farnesyl diphosphate

GPx: Glutathione-peroxidase

HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A

IPP: Isopentenyl diphosphate

IRD: Infantile Refsum disease

L-PBE (bifunctional enzyme): peroxisomal L-3-hydroxyacyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase

MCFA: Medium-chain fatty acid

MnSOD: Manganese superoxide-dismutase

MPPD: mevalonate diphosphate decarboxylase

NALD: Neonatal adrenoleukodystrophy

NBF: Nucleotide-binding fold

NSAID: Non-steroidal anti-inflammatory drug

PBD: Peroxisome biogenesis disorders

PD: Peroxisomal disorders

PED: Peroxisomal enzyme/transporter deficiency

PMP: Peroxisomal membrane proteins

PMVK: Phosphomevalonate kinase

PP: Peroxisome proliferator

PPAR: Peroxisome proliferator-activated receptor

PPP: Pex11-type peroxisome proliferator

pTH: (Human) peroxisomal thiolase
PTS: Peroxisomal targeting signal

ROS: Reactive oxygen species

SCFA: Short-chain fatty acid

SCP-2/SCPx: Sterol carrier protein 2/3-ketoacyl-CoA thiolase/Sterol carrier protein X

ThA: Thiolase A

ThB: Thiolase B

THCA: 3α,7α,12α-trihydroxy-5β-cholestanoic acid

VLCFA: Very long straight-chain fatty acid

X-ALD: X-linked adrenoleukodystrophy

ZS: Zellweger syndrome

ZSD: Zellweger spectrum disorders
1. Introduction

Peroxisomes are organelles found in every eukaryotic cell except mature erythrocytes. They were observed for the first time in mouse renal cells by Rhodin in 1954 and called microbodies. They have a diameter comprised between 0.1 – 1 μm, are surrounded by a single-membrane and contain a fine granular matrix. Several enzymes form the granular matrix that are involved in large range of processes. It was shown that peroxisomes are the only organelles whose physiological role differs according to the cell type, tissue and developmental and metabolic state of the organism. β-oxidation of fatty acids, hydrogen peroxide catabolism and defense against oxidative stresses are the most important conserved functions found in all organisms.

More than 50 enzymes have been discovered in mammalian peroxisomes that participate in various metabolic pathways including β-oxidation of very long chain fatty acids, prostaglandins, and leukotrienes (Ferdinandusse et al. 2002); biosynthesis of cholesterol, bile acids (in the liver), dolichol, and ether lipids (plasmalogens) (van den Bosch et al. 1992); oxidation of D-amino acids, polyamines, and uric acid (in non-primates) (Subramani et al. 2000; Purdue and Lazarow 2001); and detoxification of xenobiotics, and of reactive oxygen species (ROS) (Schrader and Fahimi, 2006).

In plants, peroxisomes (named glyoxisomes) are mainly involved in the glyoxylate cycle, whereas, in yeasts they are implicated in biosynthesis of lysine and the degradation of methanol and amino acids, as well as in β-oxidation (Brown and Baker, 2003).

The central role of peroxisomes for human health has been suggested by the discovery of about twenty peroxisomal disorders associated to peroxisomal biogenesis disorders or peroxisomal enzyme/transporter deficiencies.
2. Peroxisome proliferation

The amount of peroxisomes present in a cell results from different processes that can be divided into (a) peroxisome proliferation by division, (b) peroxisome de novo biogenesis, (c) peroxisome inheritance, and (d) peroxisome degradation by pexophagy, an autophagy-related process. The mechanism that regulates all these processes is not well known. Up to date, two classes of proteins, dynamin-related proteins (DRPs), and Pex11-type peroxisome proliferators (PPPs), have been recognized which are strongly involved in controlling peroxisome number and division (Thoms and Erdmann, 2005).

Many structurally diverse chemicals, known as peroxisome proliferators (PPs) are able to induce peroxisome proliferation, i.e. the process that leads to an increase in size and/or number of peroxisomes. PPs comprise drugs used for therapeutic treatment (e.g. fibrates and NSAIDs, non-steroidal anti-inflammatory drugs), industrial plasticizer di-(2-ethylhexyl) phthalate (DEHP) and environmental pollutants. In addition, physiological stimuli, such as starvation, diabetes mellitus, or high fat diets, induce peroxisome proliferation.

Peroxisome proliferation is particularly evident in the liver of rodents treated with PPs, molecules that exert their biological activity by binding to peroxisome proliferator-activated receptor α (PPARα) (Issemann and Green, 1990). PPARα activation is followed by hepatomegaly due both to hypertrophy and hyperplasia, and by induction of some peroxisomal enzymes, in particular fatty acid β-oxidation (Gonzalez et al., 1998); furthermore long-term administration of PPs leads to hepatocarcinogenesis. This last phenomenon is associated to the accumulation of oxidative stress and cell cycle derangement (Reddy, 2004; Peters et al., 2005).

During PP treatment, hepatic peroxisome content switches from 2% to 25% of the cell volume and the liver weight increases from 120%-200% (Reddy, 2004). Although the response is most dramatic in rodent liver, PPs affect other tissues such as intestine, adrenal gland, lung, cardiac and skeletal muscle and kidney (Nemali et al., 1988).
Moreover, different species do not respond in the same way to PPs. Hamsters and rabbits exhibit a modest peroxisome proliferation. In contrast, humans, guinea pigs, dogs and marmosets are either weakly responsive or nonresponsive (Lake and Gray, 1985; Reddy et al., 1986; Foxworthy et al., 1990; Richert et al., 1996).

Finally, a recent study showed that in PPARα°/° mice treated with fenofibrate, moderate peroxisomal proliferation is observable which may be imputed to an increase of a type of DRPs, i.e DLP-1 (Dynamin-Like Protein 1) expression and independent to PPARα (Zhang et al., 2006).

3. Peroxisomal biogenesis

Peroxisomal biogenesis has been extensively studied, but many questions remain unanswered. Using mutant yeasts, Chinese hamster ovary (CHO) cells and human fibroblasts, it was shown that the biogenesis involves some proteins called peroxins. Up to date, 32 peroxins have been identified, encoded by Pex genes (Distel et al., 1996; Purdue and Lazarow, 2001; Lazarow 2003; Heiland and Erdmann, 2005). Among these, there are necessary peroxisomal import receptors and peroxisomal membrane proteins (PMPs). Peroxisome generation is a conserved process from yeast to man. In humans, the deficiency of some peroxins involved in peroxisome biogenesis is associated with some serious pathologies i.e. PBD (Peroxisome biogenesis disorder).

The biogenesis of peroxisome could be subdivided in 3 steps: (i) the formation of the peroxisome membrane including the acquisition of PMPs, (ii) the import of peroxisomal matrix proteins, and (iii) the proliferation of peroxisomes (Figure 1).
3.1 Formation of peroxisome membrane (importance of ER)

The biogenesis of peroxisomes has long been matter of debate. A first model, called “growth and division” (Lazarow and Fujiki, 1985; Purdue and Lazarow, 2001) was elaborated. This model was based on the proposed idea of the possibility that peroxisomes are autonomous organelles that have evolved from an endosymbiont, in a manner similar to that of mitochondria and chloroplasts (De Duve, 1996), and also the observation that peroxisomal matrix and membrane proteins are synthesized on free ribosomes and then imported to their destination. On the contrary, Novikoff and Shin, 1964, strongly thought that peroxisomes bud off the endoplasmic reticulum because of the close resemblance between the two structures.

The “growth and division” model elaborated by Lazarow and Fujiki in 1985 has been broadly accepted for many years. This model suggested that new peroxisomes were formed by division and fission of pre-existing ones after the import of newly synthesized proteins from the cytosol. However, this hypothesis of only continuous fission of pre-existing organelles would result in exhaustion of peroxisome membranes. Recent new findings reveal the involvement of ER in the biogenesis of the peroxisomes.

Mutations in genes involved in the import of matrix proteins lead to peroxisomal “ghosts” in which membrane proteins can be found correctly inserted in the lipid bilayer (Purdue and Lazarow, 2001; Eckert and Erdmann, 2003). Exceptions are three mutants of S. cerevisiae, pex3Δ, pex16Δ and pex19Δ, in which peroxisomal membranes are completely absent. These mutants, upon the reintroduction of the corresponding wild-type gene, are able make functional peroxisomes again, suggesting that Pex3p, Pex16p and Pex19p are involved in peroxisome biogenesis. These observations are in contrast with the “growth and division” model proposed by Lazarow and Fujiki (1985) and are in agreement with the hypothesis that the ER plays a role in the origin of the peroxisomal membrane (Titorenko and Rachubinski, 1998; Mullen et al., 2001). This hypothesis
was also confirmed by Geuze et al., 2003, in mouse dendritic cells, and by Hoepfner et al., 2005, in yeast (reviewed by Kunau, 2005).

3.2 Synthesis and import of proteins in peroxisomal matrix

Peroxisomes acquire their matrix proteins by post-translational import from the cytosol. Proteins destined to peroxisome possess a peroxisomal targeting signal (PTS). Actually two types of PTS are found. Many proteins of peroxisomal matrix (about 95%) possess a PTS1 at the extreme C-terminus, consisting of the tripeptide SKL sequence or species-specific variants (Gould et al., 1989; Subramani et al., 2000). The PTS2 is found near the N-terminus of only a few matrix proteins and has the consensus sequence (R/K)(L/V/I)X₅(H/Q)(L/A) (Swinkels et al., 1991; Subramani et al., 2000). It was first identified in rat thiolase A and B (Swinkels et al., 1991).

In the cytosol, a PTS1 protein interacts with Pex5p while a PTS2 protein interacts with Pex7p. In turn, Pex7p binds to Pex14p while Pex5p binds to Pex13p and Pex14p which are peroxisomal membrane peroxins (Huhse et al., 1998; Shimizu et al., 1999). Translocation may occur through a channel formed by zinc-binding proteins Pex2p, Pex10p, and Pex12p (Huang et al., 2000; Okumoto et al., 2000). Inside the matrix, but close to the membrane, the PTS1 and PTS2 protein cargoes dissociate from their respective receptors. The PTS2 protein-targeting signal is cleaved off (Subramani, 1993). Pex5p and Pex7p are recycled out of the peroxisome, perhaps through the zinc-binding proteins or another unidentified export complex, for subsequent rounds of matrix protein binding and import. (Dammai and Subramani, 2001).
3.3 Synthesis and transport of proteins of peroxisomal membrane

Different consensus sequences for membrane protein targeting have been proposed, termed membrane PTS (mPTSs). The most common feature of the few characterized mPTSs consists of a cluster of positively charged, or basic, amino acids (Baerends et al., 2000; Mullen and Trelease, 2000). PMPs are synthesized on free ribosomes in the cytosol. A subset of PMPs, the Type II PMPs, (Sacksteder et al., 2000; Jones et al., 2001; Jones et al., 2004), appears to be directly inserted into the membrane from the cytosol, whereas the Type I PMPs are first localized into a domain on the ER from which a pre-peroxisomal vesicle forms. Each pre-peroxisomal vesicle might fuse with other vesicles or with existing peroxisomes (or could conceivably mature directly), ultimately delivering the membrane proteins to the mature peroxisome (reviewed by Johnson and Olsen, 2001).

4. Metabolic functions of mammalian peroxisomes

4.1 Peroxisomal β-oxidation

β-oxidation is the main pattern of degradation of fatty acids (FAs). In plant and yeast, this process occurs exclusively in peroxisomes, while in other eukaryotes it takes place both in peroxisomes and mitochondria. The major difference between mitochondrial and peroxisomal β-oxidations is their substrate specificity: in general, mitochondria mainly oxidize short, medium, and most long chain fatty acids, while peroxisomes preferentially oxidize very long straight-chain fatty acids (VLCFAs) (C>20) and branched-chain fatty acids (BCFAs) (Mannaerts and van Veldhoven, 1996).
The mechanism by which β-oxidation is performed is identical both in peroxisomes and mitochondria and is made up of 4 steps: (i) dehydrogenation, (ii) hydration, (iii) oxidation and (iv) thiolytic cleavage. After each cycle, fatty acids are shortened of two carbon atoms which are released as acetyl-CoA (Lazarow and De Duve 1976; Rinaldo et al., 2002; Wanders, 2004) (Figure 2).

**Dehydrogenation:** The first step is the dehydrogenation of the fatty acid CoA conjugate in trans-$\Delta^{2}$-enoyl-CoA. The enzyme catalyzes the formation of a double bond between the C-2 and C-3. In mitochondria, this reaction produces FADH$_2$ that carries high-energy electrons to the electron transport chain, helping to drive ATP synthesis. Similarly, in peroxisomal β-oxidation, FAD is involved as a cofactor, but does not produce FADH$_2$ and does not contribute to ATP production. Instead, hydrogen peroxide is formed, which is then converted to water and oxygen by the enzyme catalase.

**Hydration:** The next step is the hydration of the bond between C-2 and C-3. The reaction is stereospecific, forming only the L-3-hydroxyacyl-CoA.

**Oxidation:** In the third step the L-3-hydroxyacyl-CoA is oxidized by NAD$^+$. This converts the hydroxyl group into a keto group forming 3-ketoacyl-CoA and NADH.

**Thiolytic cleavage:** In the final step a thiol, that comes from a CoA, is inserted between C-2 and C-3 releasing an acetyl-CoA molecule and an acyl-CoA molecule, which is two carbons shorter.

In rodents, two distinct peroxisomal β-oxidation pathways are found to metabolize either straight-chain fatty acids (Reddy and Mannaerts, 1994; Wanders et al., 2000) or branched-chain fatty acids (Huyghe et al., 2001). Each pathway contains enzymes encoded by different genes.
Straight-chain fatty acyl-CoAs are catabolized by fatty acyl-CoA oxidase (ACO), peroxisomal L-3-hydroxyacyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (bifunctional enzyme: L-PBE) and peroxisomal 3-ketoacyl-CoA thiolase (thiolase).

The enzymes involved in the branched-chain fatty acids pathway include branched-chain fatty acyl-CoA oxidase, peroxisomal D-3-hydroxyacyl-CoA hydratase/D-3-hydroxyacyl-CoA dehydrogenase (bifunctional enzyme: D-PBE) and sterol carrier protein 2/3-ketoacyl-CoA thiolase (SCP-2/thiolase) also named sterol carrier protein x (SCPx).

Different names have been given to this enzyme, including D-bifunctional protein (DBP), D-peroxisomal bifunctional enzyme (D-PBE), multifunctional enzyme II (MFEII), and multifunctional protein 2 (MFP2).

The last step for straight-chain fatty acids peroxisomal β-oxidation in rodents is catalyzed by two enzymes encoded by two different genes: thiolase A (ThA) and thiolase B (ThB). The hepatic ThB gene expression is strongly regulated by peroxisome proliferators (PPs), while ThA is not affected by PP treatment.

Human peroxisomes contain two peroxisomal thiolases, i.e. pTH1 and pTH2. Human pTH1 is similar to the rodent clofibrate-inducible thiolase (Miyazawa et al., 1980), whereas pTH2 is very similar to the 58 kDa sterol carrier protein x (SCPx), with both thiolase activity and a sterol carrier protein domain (Seedorf et al., 1994). It is clear now that pTH2 (SCPx) plays a key role in the oxidation of 2-methyl branched-chain fatty acids, whereas pTH1 and pTH2 are both involved in C26:0 oxidation.

Once the fatty acid chains are reduced in length in the peroxisome, they are conjugated to carnitine and leave the peroxisome to be transported into mitochondria for further oxidation to acetyl-CoA.
4.1.1 Peroxisomal β-oxidation specific substrates

Short- and medium-chain fatty acid (SCFAs and MCFAs) derived from diet, including palmitic (C16:0), oleic (C18:1), linoleic (C18:2) and linolenic (C18:3) acid are exclusively degraded in the mitochondria, whereas peroxisomes catalyze the β-oxidation of the VLCFA such as hexacosanoic acid (C26:0), branched-chain fatty acids and other molecules as pristanic acid, di- and trihydroxycholestanoic acid (DHCA and THCA), tetracosahexaenoic acid (C24:6ω3) and long-chain dicarboxylic acids (Reddy and Hashimoto, 2001; Ferdinandusse et al., 2004). VLCFAs are in part derived from dietary sources but also formed by chain-elongation of long-chain fatty acids. In humans, most of the C26:0 is produced by chain elongation.

Moreover, although mitochondrial β-oxidation allows a complete degradation of fatty acid, peroxisomal β-oxidation is incomplete and produces medium chain acyl-CoA, (octanoyl-CoA), propionyl-CoA and acetyl-CoA. (Ferdinandusse et al., 1999; Reddy and Hashimoto, 2001). Finally, acetyl-CoA may be recycled into another β-oxidation cycle or exported out of peroxisome, while octanoyl-CoA is exported into the mitochondria to be further oxidized.

4.1.2 Activation and transport of fatty acids

Fatty acids which undergo oxidation are derived from food or from fatty acids stored in adipocytes. The breakdown of this fat is known as lipolysis. Moreover, another source of fatty acids comes from the synthesis or degradation of lipid complexes within lysosomes.

Fatty acids are imported in cell by several plasma membrane proteins, e.g. fatty acid translocase (FAT/CD36) (Bonen et al. 1999).

In the cytosol, fatty acids are quickly activated and coupled to CoA by the acyl-CoA synthetases (ACSs), which are specific for each type of fatty acid. On the contrary, acyl-CoA may be
hydrolyzed by Acyl-CoA thioesterases in free fatty acid and CoA-SH (Hunt et al., 2006). This mechanism regulates the fine balance of free fatty acids and acyl-CoA in the cell (Watkins, 1998).

Short and medium-chain fatty acids may entry by diffusion in mitochondria while transfer of long fatty acids across the inner mitochondrial membrane involves carnitine (Kerner and Hoppel, 2000).

In peroxisomes, the activated fatty acids are imported by the ATP-binding cassette transporters (ABC transporters) of peroxisome membrane. These are transmembrane proteins that function in the transport of a wide variety of substrates across extra- and intracellular membranes, including metabolic products, lipids and sterols, and drugs. Proteins are classified as ABC transporters based on the sequence and organization of their ATP-binding domain(s), also known as nucleotide-binding folds (NBFs).

Peroxisomal β-oxidation products (acetyl-CoA, octanoyl-CoA) are exported to cytosol (Ferdinandusse et al., 1999; Reddy et Hashimoto, 2001; Lamhonwah et al., 2005).

4.2 Fatty acid α-oxidation

Branched-chain fatty acids, in particular phytanic acid, which have a methyl group at the 3-position cannot be β-oxidized because the 3-methyl group blocks β-oxidation. These fatty acids, thanks to α-oxidation, which involves the oxidative decarboxylation of the 3-methyl fatty acid to produce the 2-methyl fatty acid, can be subsequently degraded by β-oxidation. In higher eukaryotes, including humans, peroxisomes are the sole site of α-oxidation.

The enzymatic machinery required for fatty acid α-oxidation has been resolved in recent years and requires the concerted action of 3 enzymes including: (i) phytanoyl-CoA hydroxylase, (ii) 2-hydroxyphytanoyl-CoA lyase and (iii) pristanal dehydrogenase (reviewed by Wierzbicki, 2007).
4.3 **Cholesterol biosynthesis**

Peroxisomes, mitochondria and ER are involved in cholesterol biosynthesis. As summarized in Figure 3, the initial conversion of acetyl-CoA to 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) occurs in peroxisomes, ER and mitochondria (Thompson et al., 1990; Hovik et al., 1991). Further conversion of HMG-CoA to mevalonate might take place both in the ER and peroxisomes, although recent studies show contradictory results (Kovacs et al., 2007). However, the following conversion of mevalonate to farnesyl diphosphate (FPP) occurs predominantly in the peroxisomes. Further metabolism of FPP to squalene proceeds exclusively in the ER, and the final conversion of lanosterol to cholesterol occurs in the ER and may also be localized to peroxisomes. Although some studies have indicated that many of the enzymes involved in these reactions are localized to the peroxisomes, the mechanisms for targeting to peroxisomes have been demonstrated at first for phosphomevalonate kinase (PMVK) and isopentenyl diphosphate (IPP) isomerase (Paton et al., 1997; Olivier et al., 1999), and subsequently for acetoacetyl-CoA thiolase, HMG-CoA synthase, mevalonate diphosphate decarboxylase (MPPD), and FPP synthase.

The HMG-CoA reductase catalyzes the conversion of HMG-CoA into mevalonate, which is the rate-limiting step of the cholesterol biosynthetic pathway. Although HMG-CoA reductase is lacking of peroxisomal targeting information, a number of studies indicate that it is located not only in the ER but also in peroxisomes (Keller et al., 1985; Keller, 1986; Engfelt et al., 1997; reviewed by Olivier et al., 2000 and Kovacs et al., 2007).

4.4 **Metabolism of bile acids**

Bile acids are the main degradation products of cholesterol, and many enzymes involved in this process are located in peroxisomes (Pedersen, 1993).
At first cholesterol is converted to $3\alpha,7\alpha,12\alpha$-trihydroxy-$5\beta$-cholestanoic acid (THCA) and $3\alpha,7\alpha$-dihydroxy-$5\beta$-cholestanoic acid (DHCA), precursors, respectively, of bile acid cholate and chenodeoxycholate (Vlahcevic et al., 1999; Setchell and O’Connell, 2001). Subsequently, after activation and transport to peroxisomes, the chain shortening of the methyl-branched side chain of THCA and DHCA is made by $\beta$-oxidation (Wanders et al., 2001).

The bile acids are conjugated to the amino acid glycine or taurine by bile acyl-CoA amino-acid $N$-acyltransferase in the hepatocyte and are stored in the gallbladder (Vlahcevic et al., 1999; Setchell and O’Connell, 2001).

4.5 Role of peroxisomes in biosynthesis of fatty acids

Peroxisomes play a very important role also in the synthesis of very long-chain fatty acids, such as docosahexaenoic acid (C22:6$\alpha$-3, DHA).

DHA is derived from the dietary essential fatty acid linolenic acid (C18:3$\alpha$-3), via a series of alternating desaturation and elongation steps (Brenner, 1971; Sprecher, 1992).

Of very important interest is the last step of the synthesis of DHA, i.e. the conversion of C22:5$\alpha$-3 to DHA. C22:5$\alpha$-3 is elongated to C24:5$\alpha$-3, desaturated to C24:6$\alpha$-3 in microsomes, and then retroconverted to C22:6$\alpha$-3 in peroxisomes (Su et al., 2001).

4.6 Synthesis of plasmalogens

Plasmalogens are ether lipids, with an ether group at the first carbon position of the glycerol. Two enzyme involved in their synthesis, acyl-dihydroxyacetone phosphate acetyl transferase and dihydroxyacetone phosphate acetyl transferase, have been isolated in peroxisomes and ER. Plasmalogen is the most abundant phospholipid in myelin. Absence of plasmalogens causes
profound abnormalities in the myelination of nerve cells, which is one of the reasons that many peroxisomal disorders lead to neurological disease. (Heymans et al., 1983).

4.7 Oxidative stress

The respiratory pathway in peroxisomes, in which electrons removed from various metabolites reduce O₂ to H₂O₂ (which is further reduced to H₂O), was first described by De Duve and Baudhuin (1966). This process is not associated with oxidative phosphorylation, and does not lead to the production of ATP. Free energy is released in the form of heat.

In addition to the generation of ROS, peroxisomes contain several ROS-metabolizing enzymes. These observations have supported the notion that these ubiquitous organelles play a key role both in the production and scavenging of ROS, in particular H₂O₂, in the cell.

ROS include radical species (containing free, i.e. unpaired, electrons), such as the superoxide anion (O₂⁻), which is formed through one-electron reduction of O₂ (O₂ + e⁻ → O₂⁻). Hydrogen peroxide (H₂O₂) is also considered a ROS, although it has no unpaired electrons, and thus it is not a radical. It can, for example, be formed by the dismutation reaction of O₂⁻ (catalyzed by superoxide dismutases) via the hydroperoxy radical (O₂⁻ + H⁺ → HO₂⁻; 2HO₂⁻ → H₂O₂ + O₂). Probably the most highly reactive and toxic form of oxygen, the hydroxyl radical (·OH), can be formed by the metal ion (e.g., iron or copper)-catalyzed decomposition of H₂O₂ (H₂O₂ + O₂⁻ → O₂ + OH⁻ + ·OH).

High levels of ROS exert a toxic effect on biomolecules such as DNA, proteins, and lipids (e.g., non-enzymatic lipoperoxidation), thus leading to i) the accumulation of oxidative damage in diverse cellular compartments, ii) the deregulation of redox-sensitive metabolic and signaling pathways, and iii) pathological events.
Several peroxisome enzymes, such as β-oxidation system, urate oxidase, xanthine oxidase, pimelic acid oxidase, sarcosine oxidase, L-α-hydroxy acid oxidase, polyamine oxidase, lead H₂O₂ production (Barroso et al., 1999).

H₂O₂ is decomposed by catalase and glutathione-peroxidase (GPx) (which is a primary cytosolic enzyme, also found in peroxisome) or converted to hydroxyl radicals (·OH). In addition to degrading the ROS, peroxisomes harbor several other powerful defense mechanisms and antioxidant enzymes. Superoxide anions (O₂⁻) generated by peroxisomal oxidases are scavenged by both manganese superoxide-dismutase (MnSOD) and copper-zinc superoxide-dismutase (CuZnSOD).

Other enzymes are able to produce ROS: i.e. nitric oxide synthase, which generates nitric oxide (·NO), a molecule with significant signaling functions in animals and plants. In particular, in animal cells, an inducible form of the enzyme (iNOS) is expressed under pathological conditions which can cause severe tissue injury (Stolz et al., 2002).

Nitric oxide synthase (NOS) catalyses the oxidation of L-arginine (L-Arg) to nitric oxide (·NO). ·NO can react with O₂⁻ radicals to form peroxynitrite (ONOO⁻), a powerful oxidant.

H₂O₂ and ·NO can cross the peroxisomal membrane and act in cellular signaling (reviewed by Schrader and Fahimi, 2006).

5. Peroxisomal disorders

In the early 1980s peroxisomal disorders (PDs) were first being recognized and described. Currently, about 16 different types of peroxisomal disorders are known (Table 1). The cause of these disorders may be associated to peroxisome biogenesis disorders (PBDs) or peroxisomal enzyme/transporter deficiencies (PEDs).
To further clarify the defective mechanisms linked to these diseases, knockout mouse models have been produced. As reported in Table 2, the silencing of genes involved in peroxisomal biogenesis or peroxisomal enzymes in mice can cause disease conditions with a large similarity to those affecting humans. On the other hand, the mutation of some genes coding for peroxisomal proteins produces no significant peroxisomal dysfunction nor diseases similar to those in humans. Knockout mouse models for PPARα (or its isotypes, i.e. PPARδ and PPARγ) are not listed in the table because these mutations, though determining some dysfunctions in the organism, do not cause peroxisomal diseases in mice.

5.1 Peroxisome biogenesis disorders (PBDs)

The PBD group comprises Zellweger spectrum disorders, ZSDs (which include Zellweger syndrome, ZS, neonatal adrenoleukodystrophy, NALD, and infantile Refsum disease, IRD), and rhizomelic chondrodysplasia punctata (RCDP) type I. Common to ZSDs are liver disease, variable neurodevelopmental delay, retinopathy, and perceptive deafness with onset in the first months of life. In addition, patients with ZS are severely hypotonic and weak from birth and have distinct facial features, peri-articular calcifications, severe brain dysfunction associated with neuronal migration disorders and die before 1 year of age. The ZS, also known as cerebro-hepato-renal syndrome, is characterized by the absence of peroxisomes in the cells of the liver, kidney, and brain (Goldfischer et al., 1973).

PBDs are associated, at molecular level, with a mutation of some peroxins indispensable for the biogenesis of peroxisome or of some peroxisomal carrier proteins. Many studies have indicated that the mutation of Pex7, which encodes the receptor for PTS2 proteins, results in RCDP type I, while the ZSDs derive from the possible mutation in 12 different genes (Pex1, 2, 3, 5, 6, 10, 12, 13, 14, 16, 19, 26) (Gould and Valle, 2000; Shimozawa et al., 2004; Wanders and Waterham, 2005).
The biochemical anomalies correlated to these diseases present an accumulation of VLCFAs (C24:0, C25:0, C26:0), THCA and DHCA (from bile acids synthesis), branched-chain fatty acid (pristanic and phytanic acid) and a decrease in synthesis of plasmalogens and DHA (Jansen et al, 2001)

5.2 Peroxisomal enzyme/transporter deficiencies (PEDs)

PEDs are disorders in which the peroxisome is intact and functioning, but a defect in one enzyme process causes the primary biochemical abnormality. Although PEDs involve the loss of even a single peroxisome function, these diseases are severe and can closely mimic the PBDs (Wanders and Waterham, 2005).

PEDs may affect different peroxisomal pathways. The most known peroxisomal diseases involve ether phospholipid synthesis (Rhizomelic chondrodysplasia punctata Type 2 due to DHAPAT deficiency), peroxisomal β-oxidation (Rhizomelic chondrodysplasia punctata Type 3 due to alkyl-DHAP synthase, X-linked adrenoleukodystrophy, acyl-CoA oxidase deficiency, D-bifunctional protein deficiency, 2-MethylacylCoA racemase deficiency, sterol carrier protein X deficiency), peroxisomal α-oxidation (Refsum disease due to phytanoyl-CoA due to hydroxylase deficiency), glyoxylate detoxification (determining hyperoxaluria Type 1) and H₂O₂-metabolism (Acatalasaemia) (Wanders and Waterham, 2005).

Diseases which involve alterations in peroxisomal β-oxidation system cause an accumulation in VLCFAs in the blood flux (Gärtner, 2000).

With the exception of X-linked adrenoleukodystrophy (X-ALD), all of these disorders are autosomal recessive.

X-ALD is characterized by a defect in the ABCD1 gene (ATP-binding cassette, subfamily D, member 1 gene) which encodes for a protein that transfers fatty acids into peroxisomes, where they undergo β-oxidation. The ABCD1 dysfunctional gene leads to the accumulation of VLCFA. It is
still unknown how the transporter affects the function of the fatty acid enzyme and, for that matter, how high levels of very long chain fatty acids cause the loss of myelin on nerve fibers (Shani and Valle, 1996). The prevalence of X-linked adrenoleukodystrophy is approximately 1 in 20,000 individuals. This condition occurs with a similar frequency in all populations.

Up to date, there is no cure for X-ALD. Some dietary treatments, for example, Lorenzo’s oil (4:1 mixture of glycerol trioleate and glycerol trierucate, the triglyceride forms of oleic and erucic acid) in combination with a diet low in VLCFA, have been used with limited success, especially before disease symptoms appear. A recent study by Moser et al (2005) shows positive long-term results with this approach.

Bone marrow transplantation has been proven to help adrenoleukodystrophy (ALD) patients who are either pre-symptomatic or exhibiting mild symptoms early in the course of the disease. The therapy with the hypolipidemic drug Lovastatin seems to normalize VLCFAs in the plasma of patients with X-ALD and increase in peroxisome, ABCD1 and Pex11α (Singh et al., 1998).

Finally, treatment is useful only to alleviate the symptoms but not to cure the disease.

6. Conclusion

A wide range of different genetic pathologies can lead to inefficiency of peroxisomal functions. In some cases the resulting diseases have comparable symptoms but, since they are determined by deficiency of different genes, a common treatment is not possible. There have been many efforts to produce biological systems, such as cell and mouse models, that could be helpful in investigating disease complications and evaluating possible alternative treatments. For example, Gueugnon et al., 2007, showed that dehydroepiandrosterone (the most abundant steroid in human) up-regulates the adrenoleukodystrophy-related gene (ABCD2), the closest homolog of ABCD1, which could be considered a potential therapeutic target for ALD-X, as functional redundancy has been demonstrated between the two proteins. Another suggested therapeutic strategy for ALD-X is
autotransplantation of genetically corrected hematopoietic stem cells using a lentiviral vector, with the aim of replacing the endogenous brain microglia from patients. Yet another approach is using stereotactic injections of viral vectors for directly targeting the ALD gene into brain glial cells (Cartier, 2001; Cartier and Aubourg, 2008).

New pathologies linked to peroxisome defaults are frequently discovered. Michelakakis et al., 2004, reported the case of the first patient who presented Leber congenital amaurosis that was subsequently demonstrated to be a PEX1 peroxisome biogenesis defect.

Currently, early diagnosis remains the best way to alleviate, when possible, disease pains. Dietary therapy with Lorenzo’s Oil has been shown to have a preventive effect by X-ALD in asymptomatic boys with normal brain magnetic resonance imaging (Moser, 2006).

Analysis of peroxisomal β-oxidation and plasmalogen synthesis on cultured cells derived from chorionic villi or amniotic fluid cells are the two most common practices for prenatal testing in the case of families at risk (Steinberg et al. 2006); while postnatal testing is carried out on blood (Shimozawa, 2007)

Difficulties of early diagnosis are due to the fact that obligate carriers, such as those for ZS and RCDP disorders, do not express partial defects. Thus, although prenatal diagnosis is possible, prenatal counseling for unaware couples is not done habitually.

As discussed previously, a definitive cure for these peroxisomal diseases is not yet possible, but in the author’s opinion, as regards X-ALD (and the main phenotypes of this, such as the childhood cerebral form, CCALD, and the adrenomyeloneuropathy, AMN) three different therapeutic approaches must be mentioned which could strongly block disease progression and offer good perspective for the future. A study done by Genin et al., 2009, shows that pharmacological treatment with a thyroid hormone homolog, CGS 23425 (which does not show the typical side effects on heart, bones and muscles of thyroid hormones), can up regulate ABCD2 in different models, compensating ABCD1 lacking. Currently, this study is in the preclinical stage, but results are encouraging. Two other therapeutic approaches have provided enthusiastic results. As
mentioned, Cartier and Aubourg, 2008, propose a transplantation of autologous hematopoietic stem cells genetically modified to express the missing protein, thus avoiding problems associated with allogeneic hematopoietic stem-cell transplantation. This strategy has now reached the stage of phase I/II clinical trials to assess safety and potential efficacy. A second study, in an advanced stage, reports a successful cord blood transplantation using a reduced-intensity conditioning regimen to reduce regimen-related toxicity and transplant-associated morbidity and mortality for advanced childhood-onset cerebral adrenoleukodystrophy. The treatment was well tolerated, stopped disease progression and contributed to a good neuropsychological outcome (Awaya et al., 2009).

In recent times, researchers have begun to understand more about peroxisomal disorders, but the only aid that can currently be given to patients is to slow down the beginning symptoms. Unfortunately, the phenotypes associated with peroxisomal defects are not clear and treatment may be ineffective when disease symptoms arise. Furthermore, more and more diseases have only recently been found to be related to peroxisomal disorders.

Acknowledgments

I wish to thank Pr. Claudia Sartori for her critical reading of the manuscript.

Bibliography


neuronal migration and endochondral ossification in Pex7 knockout mice: a model for rhizomelic chondrodysplasia punctata., Hum Mol Genet; 12(18):2255-67


Faust PL, Hatten ME (1997) Targeted deletion of the PEX2 peroxisome assembly gene in mice provides a model for Zellweger syndrome, a human neuronal migration disorder., J Cell Biol;139(5):1293-305


Kovacs WJ; Tape KN; Shackelford JE; Wikander TM; Richards MJ; Fliesler SJ; Krisans SK; Faust PL (2009) Peroxisome deficiency causes a complex phenotype because of hepatic SREBP/Insig dysregulation associated with endoplasmic reticulum stress., J Biol Chem; 284(11):7232-45


Li X, Baumgart E, Morrell JC, Jimenez-Sanchez G, Valle D, Gould SJ (2002) PEX11 beta deficiency is lethal and impairs neuronal migration but does not abrogate peroxisome function., Mol Cell Biol; 22(12):4358-65 (b)


Setchell KDR, O’Connell NC (2001) in Liver Disease in Children (Suchy FJ, Sokol RJ, Balistreri WF, eds), 2nd Ed., pp. 701-733, Lippincott Williams & Wilkins, Philadelphia


Table 1. **Peroxisomal disorders**

<table>
<thead>
<tr>
<th>Peroxisomal enzyme/transporter deficiencies (PEDs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhizomelic chondrodysplasia punctata Type 2 (DHAPAT deficiency)</td>
</tr>
<tr>
<td>Rhizomelic chondrodysplasia punctata Type 3 (alkyl-DHAP synthase)</td>
</tr>
<tr>
<td>X-linked adrenoleukodystrophy</td>
</tr>
<tr>
<td>Acyl-CoA oxidase deficiency</td>
</tr>
<tr>
<td>D-bifunctional protein deficiency</td>
</tr>
<tr>
<td>2-MethylacylCoA racemase deficiency</td>
</tr>
<tr>
<td>Sterol carrier protein X deficiency</td>
</tr>
<tr>
<td>Refsum disease (phytanoyl-CoA hydroxylase deficiency)</td>
</tr>
<tr>
<td>Hyperoxaluria Type 1</td>
</tr>
<tr>
<td>Acatalasaemia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peroxisome biogenesis disorders (PBDs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zellweger spectrum disorders, ZSDs</td>
</tr>
<tr>
<td>Zellweger syndrome, ZS</td>
</tr>
<tr>
<td>Neonatal adrenoleukodystrophy, NALD</td>
</tr>
<tr>
<td>Infantile Refsum disease, IRD</td>
</tr>
</tbody>
</table>

<p>| Rhizomelic chondrodysplasia punctata (RCDP) type 1                                       |</p>
<table>
<thead>
<tr>
<th>Silenced gene(s)</th>
<th>Affected Anatomical Systems in Mouse</th>
<th>Similar Human Diseases</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pex2</td>
<td>Lethality/prenatal-perinatal, lethality/postnatal, embryogenesis, behavior, craniofacial, endocrine/exocrine, growth/size, homeostasis, liver/biliary, skeleton, nervous system, renal/urinary</td>
<td>Zellweger Syndrome</td>
<td>Faust and Hatten, 1997; Kovacs et al., 2009</td>
</tr>
<tr>
<td>Pex5</td>
<td>Lethality/postnatal, digestive/alimentary, embryogenesis, growth/size, liver/biliary, muscle, renal/urinary, respiratory, nervous system</td>
<td>Zellweger Syndrome</td>
<td>Baes et al., 1997; Hulshagen et al., 2008</td>
</tr>
<tr>
<td>Pex7</td>
<td>Lethality/prenatal-perinatal, behavior, endocrine/exocrine, growth/size, homeostasis, reproductive, skeleton, vision/eye, nervous system, muscle, hematopoietic, immune</td>
<td>Rhizomelic Chondrodysplasia</td>
<td>Brites et al., 2003</td>
</tr>
<tr>
<td>Pex11α</td>
<td>Cellular, liver/biliary</td>
<td>Rhizomelic Chondrodysplasia Punctata, Type 1; RCDP1</td>
<td>Li et al., 2002</td>
</tr>
<tr>
<td>Pex11β</td>
<td>Lethality/prenatal-perinatal, behavior, cellular, craniofacial, growth/size, homeostasis, liver/biliary, skeleton, nervous system</td>
<td>Zellweger Syndrome</td>
<td>Li et al., 2002 (b)</td>
</tr>
<tr>
<td>Pex13</td>
<td>Lethality/prenatal-perinatal, cellular, growth/size</td>
<td>Zellweger Syndrome</td>
<td>Li et al., 2002</td>
</tr>
<tr>
<td>ABCD1</td>
<td>Homeostasis, reproductive</td>
<td>X-linked adrenoleukodystrophy</td>
<td>Forss-Petter et al., 1997</td>
</tr>
<tr>
<td>ABCD1</td>
<td>Homeostasis, behavior, nervous system, endocrine/exocrine, hematopoietic, immune</td>
<td>X-linked adrenoleukodystrophy</td>
<td>Lu et al., 1997</td>
</tr>
<tr>
<td>ABCD2</td>
<td>Homeostasis, nervous system, behavior, hematopoietic, immune</td>
<td>X-linked adrenoleukodystrophy</td>
<td>Kobayashi et al., 1997</td>
</tr>
<tr>
<td>ABCD1; ABCD2</td>
<td>Homeostasis, nervous system, behavior, endocrine/exocrine, immune, hematopoietic</td>
<td></td>
<td>Pujol et al., 2004</td>
</tr>
<tr>
<td>Slc27a2</td>
<td>Cellular</td>
<td></td>
<td>Heinzler et al., 2003</td>
</tr>
<tr>
<td>ABCD1; Slc27a2</td>
<td>Same phenotype Abcd1 knockout mouse</td>
<td></td>
<td>Heinzer et al., 2003</td>
</tr>
<tr>
<td>Acox1</td>
<td>Tumorigenesis, liver/biliary, homeostasis, reproductive, growth/size, endocrine/exocrine</td>
<td>Peroxisomal Acyl-Coa Oxidase Deficiency; Peroxisome Biogenesis Disorders</td>
<td>Fan et al., 1996</td>
</tr>
<tr>
<td>Ehhadh</td>
<td>Cellular, homeostasis</td>
<td></td>
<td>Qi et al., 1999</td>
</tr>
<tr>
<td>Hsd17b4</td>
<td>Lethality/postnatal, growth/size, digestive/alimentary, reproductive, homeostasis, behavior, vision/eye</td>
<td>D-Bifunctional Protein Deficiency</td>
<td>Baes et al., 2000</td>
</tr>
<tr>
<td>Hsd17b4; Ehhadh</td>
<td>Lethality/prenatal-perinatal, lethality/postnatal, growth/size, behavior, homeostasis, liver/biliary, cellular, muscle</td>
<td>D-Bifunctional Protein Deficiency</td>
<td>Jia et al., 2003</td>
</tr>
<tr>
<td>Amacr</td>
<td>Life span/aging, adipose, growth/size, homeostasis, liver/biliary</td>
<td>Alpha-Methylacyl-Coa Racemase deficiency</td>
<td>Savolainen et al., 2004</td>
</tr>
<tr>
<td>Gnpat</td>
<td>Life span/aging, pigmentation, endocrine/exocrine, growth/size, homeostasis, limbs/digits/tail, reproductive, vision/eye, nervous system</td>
<td>Rhizomelic Chondrodysplasia Punctata, Type 2, RCDP2</td>
<td>Rodemer et al., 2003</td>
</tr>
<tr>
<td>Phyh</td>
<td>Homeostasis, nervous system, behavior, liver/biliary, adipose, reproductive, growth/size, immune</td>
<td>Refsum Disease</td>
<td>Ferdinandusse et al., 2008</td>
</tr>
<tr>
<td>Agxt</td>
<td>Renal/urinary, other, homeostasis</td>
<td>Primary hyperoxaluria</td>
<td>Salido et al., 2006</td>
</tr>
<tr>
<td>Cat</td>
<td>Cellular</td>
<td></td>
<td>Ho et al., 2004</td>
</tr>
<tr>
<td>Acaa1b (or ThB)</td>
<td>Growth/size, endocrine, altered MUFA synthesis when metabolically stressed (Wy14,643) (in characterizing)</td>
<td></td>
<td>Chevillard et al., 2004; Personal communication</td>
</tr>
</tbody>
</table>
Legend

Figure 1. Model of peroxisome biogenesis. ER is involved in de novo biogenesis of peroxisome. Mature peroxisomes acquire proteins from free ribosomes and can proliferate by division (adapted from Thoms and Erdmann, 2005, and Holroyd and Erdmann, 2001)

Figure 2. Mechanism of β-oxidation in peroxisome and mitochondria. The mechanism by which fatty acids are degraded in peroxisomes and mitochondria is identical. Each pathway contains enzymes encoded by different genes. On the right side of the figure are shown the enzyme found in the peroxisome of the rodents and involved in peroxisomal β-oxidation (modified from www.biocarta.com/pathfiles/boxnpPathway.asp)

Figure 3. Cholesterol biosynthesis. The synthesis of cholesterol is carried out in different cell organelles, i.e. mitochondria, peroxisome and ER. The question marks indicate the probably pathways not yet confirmed (modified by Kovacs et al., 2007)

Table 1: Peroxisomal disorders

Table 2. Knockout mouse models & peroxisomal disease affecting humans. The table lists the silenced gene in knockout mouse models and the main observable consequences. Abbreviations: Pex11α (peroxisomal biogenesis factor 11 α), Pex11β (peroxisomal biogenesis factor 11 β), Pex13 (peroxisomal biogenesis factor 13), Pex5 (peroxisomal biogenesis factor 5), Pex2 (peroxisomal membrane protein 2), Pex7 (peroxisomal biogenesis factor 7), ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1), ABCD2 (ATP-binding cassette, sub-family D [ALD], member 2), Slc27a2 (solute carrier family 27 [fatty acid transporter], member 2), Acox1 (acyl-Coenzyme A oxidase 1, palmitoyl), Ehhadh (enoyl-Coenzyme A hydratase/3-hydroxyacyl Coenzyme A...
dehydrogenase), Hsd17b4 (hydroxysteroid [17-beta] dehydrogenase 4), Amacr (alpha-methylacyl-CoA racemase), Gnpat (glyceronephosphate O-acyltransferase), Phyh (phytanoyl-CoA hydroxylase), Agxt (alanine-glyoxylate aminotransferase), Cat (catalase), Acaa1b (or ThB) (acetyl-Coenzyme A acyltransferase 1B).